PURPOSE: To test whether a novel bifunctional chimeric peptide comprising a cyclic Arg-Gly-Asp pentapeptide covalently bound to an echistatin domain can discriminate alpha(v)beta(3) from alpha(v)beta(5) integrin, thus allowing the in vivo selective visualization of alpha(v)beta(3) expression by single-photon and positron emission tomography (PET) imaging. EXPERIMENTAL DESIGN: The chimeric peptide was preliminarily tested for inhibition of alpha(v)beta(3)-dependent cell adhesion and competition of 125I-echistatin binding to membrane of stably transfected K562 cells expressing alpha(v)beta(3) (Kalpha(v)beta(3)) or alpha(v)beta(5) (Kalpha(v)beta(5)) integrin. The chimeric peptide was then conjugated with diethylenetriaminepentaacetic acid and labeled with 111In for single-photon imaging, whereas a one-step procedure was used for labeling the full-length peptide and a truncated derivative, lacking the last five C-terminal amino acids, with 18F for PET imaging. Nude mice bearing tumors from Kalpha(v)beta(3), Kalpha(v)beta(5), U87MG human glioblastoma, and A431 human epidermoid cells were subjected to single-photon and PET imaging. RESULTS: Adhesion and competitive binding assays showed that the novel chimeric peptide selectively binds to alpha(v)beta(3) integrin and does not cross-react with alpha(v)beta(5). In agreement with in vitro findings, single-photon and PET imaging studies showed that the radiolabeled chimeric peptide selectively localizes in tumor xenografts expressing alphavbeta3 and fails to accumulate in those expressing alpha(v)beta(5) integrin. When 18F-labeled truncated derivative was used for PET imaging, alphavbeta3- and alpha(v)beta(5)-expressing tumors were visualized, indicating that the five C-terminal amino acids are required to differentially bind the two integrins. CONCLUSION: Our findings indicate that the novel chimeric Arg-Gly-Asp peptide, having no cross-reaction with alphavbeta5 integrin, allows highly selective alphavbeta3 expression imaging and monitoring.
PURPOSE: To test whether a novel bifunctional chimeric peptide comprising a cyclic Arg-Gly-Asp pentapeptide covalently bound to an echistatin domain can discriminate alpha(v)beta(3) from alpha(v)beta(5) integrin, thus allowing the in vivo selective visualization of alpha(v)beta(3) expression by single-photon and positron emission tomography (PET) imaging. EXPERIMENTAL DESIGN: The chimeric peptide was preliminarily tested for inhibition of alpha(v)beta(3)-dependent cell adhesion and competition of 125I-echistatin binding to membrane of stably transfected K562 cells expressing alpha(v)beta(3) (Kalpha(v)beta(3)) or alpha(v)beta(5) (Kalpha(v)beta(5)) integrin. The chimeric peptide was then conjugated with diethylenetriaminepentaacetic acid and labeled with 111In for single-photon imaging, whereas a one-step procedure was used for labeling the full-length peptide and a truncated derivative, lacking the last five C-terminal amino acids, with 18F for PET imaging. Nude mice bearing tumors from Kalpha(v)beta(3), Kalpha(v)beta(5), U87MG humanglioblastoma, and A431 human epidermoid cells were subjected to single-photon and PET imaging. RESULTS: Adhesion and competitive binding assays showed that the novel chimeric peptide selectively binds to alpha(v)beta(3) integrin and does not cross-react with alpha(v)beta(5). In agreement with in vitro findings, single-photon and PET imaging studies showed that the radiolabeled chimeric peptide selectively localizes in tumor xenografts expressing alphavbeta3 and fails to accumulate in those expressing alpha(v)beta(5) integrin. When 18F-labeled truncated derivative was used for PET imaging, alphavbeta3- and alpha(v)beta(5)-expressing tumors were visualized, indicating that the five C-terminal amino acids are required to differentially bind the two integrins. CONCLUSION: Our findings indicate that the novel chimeric Arg-Gly-Asp peptide, having no cross-reaction with alphavbeta5 integrin, allows highly selective alphavbeta3 expression imaging and monitoring.
Authors: Yunpeng Ye; Walter Akers; Baogang Xu; Sharon Bloch; Charles Odonkor; Samuel Achilefu Journal: Bioorg Med Chem Lett Date: 2012-07-20 Impact factor: 2.823
Authors: Riikka Siitonen; Emilia Peuhu; Anu Autio; Heidi Liljenbäck; Elina Mattila; Olli Metsälä; Meeri Käkelä; Tiina Saanijoki; Ingrid Dijkgraaf; Sirpa Jalkanen; Johanna Ivaska; Anne Roivainen Journal: J Nucl Med Date: 2019-03-08 Impact factor: 10.057
Authors: Wei Lu; Marites P Melancon; Chiyi Xiong; Qian Huang; Andrew Elliott; Shaoli Song; Rui Zhang; Leo G Flores; Juri G Gelovani; Lihong V Wang; Geng Ku; R Jason Stafford; Chun Li Journal: Cancer Res Date: 2011-08-19 Impact factor: 12.701
Authors: D Ma; X Xu; S An; H Liu; X Yang; J F Andersen; Y Wang; F Tokumasu; J M C Ribeiro; I M B Francischetti; R Lai Journal: Thromb Haemost Date: 2011-04-07 Impact factor: 5.249
Authors: Gaetano Santulli; Maria Felicia Basilicata; Mariarosaria De Simone; Carmine Del Giudice; Antonio Anastasio; Daniela Sorriento; Michele Saviano; Annarita Del Gatto; Bruno Trimarco; Carlo Pedone; Laura Zaccaro; Guido Iaccarino Journal: J Transl Med Date: 2011-01-13 Impact factor: 5.531